Currently, without FDA approval, the approval to raise the limit of common stock and have a new preferred stock hurts. It won't matter if you have an increase in revenues above the $5M projected. The only thing that might do is to limit how much further the stock will drop. As of right now, the price of the stock now is not going to hold. It will drop. There isn't much support (based on level II)